Gracell Biotechnologies to Host Clinical Update Conference Call and Webcast on June 4, 2021 at 11:00am EDT

Rhea-AI Summary

Gracell Biotechnologies (NASDAQ: GRCL) announced a conference call on June 4, 2021, at 11:00 am ET to discuss results from a Phase 1 study of its FasTCAR-enabled CAR-T cell therapy, GC012F, targeting relapsed/refractory multiple myeloma. The study's data will be presented at the 2021 American Society of Clinical Oncology Annual Meeting. Investors can join via domestic dial-in at 877-407-0784 or international dial-in at +1 201-689-8560. A live webcast will also be available, with a replay accessible for 90 days post-event.

SUZHOU, China and PALO ALTO, Calif., May 21, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will host a conference call and webcast to present an update on the results of a Phase 1 first-in-human multicenter investigator-initiated study of the FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T cell therapy GC012F in relapsed/refractory multiple myeloma. This data was accepted as poster presentation at the 2021 American Society of Clinical Oncology Annual Meeting.

Conference call and webcast details:
Friday, June 4, 2021 @ 11:00 am ET
Investor domestic dial-in: 877-407-0784
Investor international dial-in: +1 201-689-8560
Conference ID: 13719675
Live webcast link: https://ir.gracellbio.com/news-events/events-and-presentations
A replay of the webcast will be available on ir.gracellbio.com shortly after the conclusion of the event for 90 days.

About Gracell
Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit www.gracellbio.com

Follow @GracellBio on LinkedIn

Media contact
Marvin Tang
marvin.tang@gracellbio.com

Investor contact
Gracie Tong
gracie.tong@gracellbio.com

FAQ

What is the purpose of Gracell's conference call on June 4, 2021?

Gracell's conference call on June 4, 2021, is to present results from a Phase 1 study of its GC012F CAR-T cell therapy for multiple myeloma.

When will Gracell present data on its CAR-T cell therapy?

Gracell will present data on its CAR-T cell therapy GC012F during a conference call on June 4, 2021.

What therapy will Gracell discuss during the June 4 conference call?

Gracell will discuss its FasTCAR-enabled CAR-T cell therapy GC012F targeting multiple myeloma.

Where will Gracell present the results of its Phase 1 study?

The results of Gracell's Phase 1 study will be presented at the 2021 American Society of Clinical Oncology Annual Meeting.

How can investors access Gracell's conference call?

Investors can access Gracell's conference call via domestic dial-in at 877-407-0784 or international dial-in at +1 201-689-8560.